Journal of Medicinal Chemistry p. 9061 - 9077 (2019)
Update date:2022-08-17
Topics:
Shaik, Anver Basha
Kumar, Vivek
Bonifazi, Alessandro
Guerrero, Adrian M.
Cemaj, Sophie L.
Gadiano, Alexandra
Lam, Jenny
Xi, Zheng-Xiong
Rais, Rana
Slusher, Barbara S.
Newman, Amy Hauck
Dopamine D3 receptors (D3R) play a critical role in neuropsychiatric conditions including substance use disorders (SUD). Recently, we reported a series of N-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1H-indole-2-carboxamide analogues as high affinity and selective D3R lead molecules for the treatment of opioid use disorders (OUD). Further optimization led to a series of analogues that replaced the 3-OH with a 3-F in the linker between the primary pharmacophore (PP) and secondary pharmacophore (SP). Among the 3-F-compounds, 9b demonstrated the highest D3R binding affinity (Ki = 0.756 nM) and was 327-fold selective for D3R over D2R. In addition, modification of the PP or SP with a 3,4-(methylenedioxy)phenyl group was also examined. Further, an enantioselective synthesis as well as chiral HPLC methods were developed to give enantiopure R- and S-enantiomers of the four lead compounds. Off-target binding affinities, functional efficacies, and metabolic profiles revealed critical structural components for D3R selectivity as well as drug-like features required for development as pharmacotherapeutics.
View MoreDoi:10.1016/j.cattod.2012.05.002
(2013)Doi:10.1039/C29710000390
(1971)Doi:10.1139/v75-429
(1975)Doi:10.1039/c1dt10201j
(2011)Doi:10.1016/j.bmcl.2015.12.095
(2016)Doi:10.1002/pssa.200566177
(2006)